Cual es la diferencia entre afinidad y eficacia?

Afinidad es que tan fuerte se une el peptido al receptor (Kd). Eficacia es que tan bien activa el receptor una vez unido (actividad intrinseca). Un peptido puede tener alta afinidad pero baja eficacia (partial agonist) o viceversa.

Que es el residence time y por que importa?

Tiempo que el peptido permanece unido al receptor. Inverso de Koff. Residence time largo significa bloqueo o activacion prolongada. Puede ser mas importante que afinidad para efecto in vivo, determinando duracion de accion.

Como se mide Kd por SPR?

Surface plasmon resonance mide union en tiempo real. Se inyecta peptido a diferentes concentraciones sobre receptor immobilizado. La curva de asociacion da Kon, la de disociacion da Koff. Kd = Koff/Kon. Metodo directo sin marcador.

Que es biased agonism?

Cuando un agonista activa preferencialmente ciertas vias de senalizacion sobre otras. Ejemplo: favorecer G protein signaling vs beta-arrestin. Permite efectos terapeuticos con menos efectos secundarios de vias no deseadas.

Optimizacion de Potencia en Peptidos

Categorías: Metodología de Investigación, Información General

La optimizacion de potencia es un objetivo central en el desarrollo de peptidos terapeuticos. Mayor afinidad y eficacia se traducen en mejores resultados clinicos.

Resumen Simplificado

Interacciones adicionales, pre-organizacion y optimizacion de farmacoforos aumentan potencia.

Conceptos de potencia

Potencia tiene multiples facets. Binding affinity. Kd. Equilibrium constant. Lower is better. nM range therapeutic. pM ultrahigh affinity. Functional potency. IC50. Inhibition constant. EC50. Effective concentration. In vitro assay. Cell-based. May differ. Efficacy. Maximum effect. Intrinsic activity. Full agonist. Partial agonist. Antagonist. Inverse agonist. Affinity vs efficacy. Related but distinct. High affinity. Not always high efficacy. Relationship. Binding enables effect. Efficacy determines magnitude. Therapeutic relevance. Potency affects dose. Lower dose needed. Better safety potentially. Cost of goods. Less drug needed. Trade-offs. Too high potency. Narrow therapeutic window. Safety issues. Potency is key parameter. Optimization target.

Mejora de afinidad

Affinity mejora con estrategia. Structural analysis. Examine binding mode. Identify gaps. Missing interactions. Unfilled pockets. Weak contacts. Addition strategies. Extend sequence. Add residues. Contact more surface. Optimize existing. Better geometry. Stronger bonds. Replace weak interactions. Add H-bonds. Add salt bridges. Add hydrophobic contacts. Entropy optimization. Pre-organize peptide. Reduce flexibility. Cyclization. Constrainted residues. Reduce entropy loss upon binding. Conformationally locked. Lower penalty. Binding energy = enthalpy - entropy. Entropic cost reduced. Net affinity improved. Complementary interactions. Shape complementarity. Electrostatic complementarity. Water displacement. Release bound water. Entropy gain. Affinity improvement requires understanding. Structure guides design.

Eficacia agonista

Efficacy para agonistas importa. Definition. Ability to activate receptor. Full response. vs partial. Mechanism. Receptor conformation. Active state induced. Signaling cascade. Efficacy determinants. Binding orientation. Contact residues. Conformational change. Receptor activation. Optimizing efficacy. Understand activation. What conformational change. Which contacts critical. Active state stabilizers. Enhance productive contacts. Reduce inactive state binding. Biased agonism. Different pathways. G protein vs arrestin. Therapeutic selectivity. Signaling bias desirable. Efficacy measurement. Functional assays. Second messengers. Downstream effects. Cellular response. In vivo response. Maximum effect. Efficacy vs affinity. High affinity partial agonist. May be less effective. Than moderate affinity full agonist. Context matters. Efficacy optimization is nuanced. Mechanism understanding required.

Optimizacion de antagonistas

Antagonists block activity. Types. Competitive. Same site as agonist. Reversible. Irreversible. Covalent binding. Non-competitive. Different site. Allosteric block. Optimization goals. Binding affinity. High affinity needed. Block agonist. Outcompete. Residence time. Long duration. Slow off-rate. Selectivity. Block only target. Not related receptors. Strategies. Maximum occupancy. Highest affinity. Fill binding site. Block access. Unbeatable binding. Contact all hot spots. Displace agonist completely. Allosteric modulation. Non-competitive approach. May be more selective. Different site. Less conserved. Antagonist advantage. No need for efficacy. Pure binding optimization. Simpler. But still needs selectivity. Duration of action. Long residence time. Sustained block. Less frequent dosing. Antagonists are binding competitions. Affinity wins.

Medicion de potencia

Medicion precisa es critica. Binding assays. SPR. Kd direct. ITC. Thermodynamics. MST. Solution-based. FP. Fluorescence polarization. Filter binding. Radioligand. Competition binding. Ki determination. Cheng-Prusoff equation. Functional assays. cAMP. Second messenger. Calcium flux. Reporter genes. Cell proliferation. Enzyme activity. In vivo. Dose-response. Full curve. Multiple concentrations. Appropriate range. Hill slope. Cooperativity. Statistical analysis. Curve fitting. Confidence intervals. Replicate. Independent experiments. Reproducibility. Reference standards. Compare to known compounds. Assay validation. Z-prime factor. Signal-to-noise. Dynamic range. Quality control. Regular checks. Potency data quality. Determines reliability. Poor assay. Misleading optimization.

Limites practicos

Potencia tiene limites. Biological ceiling. Receptor density. Maximum effect achievable. Bivalent binding. Chelate effect. Ultra-high affinity possible. But not always useful. Diminishing returns. 10-fold improvement. May not translate clinically. Cost of synthesis. Complex analogs. Expensive. Manufacturing burden. Other properties. May suffer. Selectivity compromised. PK worse. Stability reduced. Therapeutic window. Too potent. Narrow window. Safety risk. Practical potency. nM to low uM. Typically sufficient. Ultra-high not always needed. Balance. Potency vs other attributes. Multi-parameter optimization. Context-dependent. Some targets need ultrahigh. Others work with moderate. Know your target. Know your disease. Understand requirements. Potency is one parameter. Not the only goal.

Hallazgos Clave

La potencia incluye afinidad de union y eficacia funcional, que son distintas
La afinidad mejora anadiendo interacciones y reduciendo costo entropico
La eficacia agonista depende de estabilizar el estado activo del receptor
Los antagonistas compiten por afinidad; residencia larga mejora duracion
SPR, ITC y assays funcionales miden diferentes aspectos de potencia
Ultra-alta potencia puede comprometer selectividad y otras propiedades

Más artículos en Metodología de Investigación

Más artículos en Información General

Términos del glosario

Preguntas frecuentes

Cual es la diferencia entre afinidad y eficacia?: Afinidad es que tan fuerte se une el peptido al receptor (Kd). Eficacia es que tan bien activa el receptor una vez unido (actividad intrinseca). Un peptido puede tener alta afinidad pero baja eficacia (partial agonist) o viceversa.
Que es el residence time y por que importa?: Tiempo que el peptido permanece unido al receptor. Inverso de Koff. Residence time largo significa bloqueo o activacion prolongada. Puede ser mas importante que afinidad para efecto in vivo, determinando duracion de accion.
Como se mide Kd por SPR?: Surface plasmon resonance mide union en tiempo real. Se inyecta peptido a diferentes concentraciones sobre receptor immobilizado. La curva de asociacion da Kon, la de disociacion da Koff. Kd = Koff/Kon. Metodo directo sin marcador.
Que es biased agonism?: Cuando un agonista activa preferencialmente ciertas vias de senalizacion sobre otras. Ejemplo: favorecer G protein signaling vs beta-arrestin. Permite efectos terapeuticos con menos efectos secundarios de vias no deseadas.

Volver a la biblioteca de investigación